Anti-CD6 Antibody for Selective Th17 Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and chronic inflammatory diseases, such as multiple sclerosis, are nonspecific and have serious side effects, as they primarily suppress TNF-alpha function, which can be ineffective for certain patients and lead to undesirable side effects, while there is a need for targeted therapies that modulate T-helper 17 (Th17) and T-helper 1 (Th1) cell-mediated inflammatory responses.
Innovation Solution
The use of an anti-CD6 binding partner, specifically an antibody like Itolizumab, which binds to CD6 and co-stimulates with anti-CD3, selectively suppresses Th17 and Th1-mediated inflammatory responses by reducing the production of IL-23R, thereby decreasing inflammation in autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonspecific suppressants of TNF-alpha function are used for treatment, then inflammatory responses are suppressed, but side effects increase and effectiveness decreases for certain patients
Solution Approach 1:
The patent segments the inflammatory response pathway by specifically targeting Th17 and Th1 cell populations through anti-CD6 antibodies, rather than using nonspecific TNF-alpha suppressants. This segmentation allows selective modulation of pathogenic T cell responses while preserving other immune functions, thereby improving treatment effectiveness and reducing side effects associated with broad immunosuppression.
Solution Approach 2:
The invention applies local quality by directing therapeutic action specifically at Th17 and Th1 cells through CD6 binding, rather than uniformly suppressing all inflammatory pathways. This localized approach targets the specific cell populations responsible for autoimmune pathology while maintaining the functionality of other immune cells, thus improving the risk-benefit ratio of the treatment.
2Reliability
If targeted therapies modulating Th17 and Th1 cell responses are developed, then treatment specificity improves, but therapeutic options and complexity increase
Solution Approach 1:
The anti-CD6 binding partner exhibits multi-functionality by simultaneously achieving several therapeutic objectives: it selectively suppresses Th17 and Th1 cell responses, reduces cytokine production (IL-17, IFN-gamma), and modulates inflammatory pathways. This single agent addresses multiple aspects of autoimmune pathology, providing a versatile therapeutic tool that improves treatment specificity without requiring a complex combination of multiple drugs.
Data Source
Figure 1
Figure 2
Figure 3A~3E
AI summary
The present disclosure relates to a Itolizumab antibody or a functional fragment thereof for use in the treatment of Inflammatory Bowel Disease in a subject having an increased number of T helper 17 (Thl7) cells when compared to a healthy subject, wherein the use suppresses the production of the cytokine receptor IL-23R, thereby decreasing inflammation mediated by Thl7 cells.